Remdesivir-associated bradycardia.

Patrick R Ching, Calvin Lee

BMJ case reports 2021 Sep 03

filter terms:

Remdesivir is an antiviral used for the treatment of COVID-19 requiring hospitalisation. Information on its cardiovascular safety profile is scarce. We report the case of a 37-year-old man with COVID-19 who developed bradycardia after receiving remdesivir. We recommend a baseline ECG for all patients prior to receiving remdesivir and continuous cardiac monitoring during treatment, especially among those with underlying cardiovascular disease, elderly and using β-blockers. © BMJ Publishing Group Limited 2021. No commercial re-use. See rights and permissions. Published by BMJ.